ARCHIVES

FDA Proposal On Dissemination of Off-Label Drug Information Doesn’t Go Far Enough, Cancer Groups Say

This article is from The Cancer Letter archive.

Vol. 22 No. 04 | January 26, 1996

Download PDF Visit The Full Archive

Related Articles

Phase III Alimta Trial Fails To Extend Progression-Free Survival Without Grade 4 Adverse Events

June 28, 2013

Funding opportunities listed.

March 26, 2004

Children With Recurrent Hodgkin’s Respond To Gemcitabine, Vinorelbine

March 27, 2009

Archival photos: Senator Ernest “Fritz” Hollings, namesake of MUSC Hollings Cancer Center

February 2, 2021

DCE Board Approves Epidemiology Contract Recompetitions

March 17, 1995

DCT Board Okays Concepts For New Trials In Imaging, Intraoperative RT

June 14, 1985